Primex Pharmaceuticals and POA Pharma Sign a Strategic Partnership to Commercialise OZALIN in the Nordic Region

Gothenburg, Sweden and Zug, Switzerland (ots/PRNewswire) - POA
Pharma Scandinavia AB, a market-oriented Boutique Healthcare Company,
working in close contact with healthcare organizations, professionals
and hospitals in Nordic countries and Primex Pharmaceuticals AG, an
innovative Anaesthesia pharmaceutical company, today announced a
strategic agreement to launch OZALIN® in Denmark, Finland, Norway and
Sweden.

One of the challenges facing paediatric anaesthetists in treating
children, either for premedication prior to surgery or during
procedural sedation, is the lack of acceptable approved medications.
An oral solution for children older than 6 months, OZALIN®, has been
approved in several markets in the EU.

"The agreement with POA Pharma represents an important achievement
for Primex Pharmaceuticals and underscores our commitment to making
OZALIN® available to anaesthetists across all EU member states," said
Alan Knox, Primex's Group CEO. "We are confident that POA Pharma
expertise in the field of anaesthesia, coupled with their
understanding of the Nordic countries, will benefit children
requiring premedication or procedural sedation."

Tina Madsen Sandstr?m, CEO of POA, "POA Pharma is looking forward
to launch OZALIN® to our patients and clinical customers in the
Nordic markets. We are happy to once again having the opportunity to
introduce new developments within the health care sector."

About Primex Pharmaceuticals:

Primex Pharmaceuticals is a leading global innovative anaesthesia
company, expanding in paediatric pharmaceuticals. Primex brings a
broad portfolio of anaesthesia products helping patients undergo a
wide range of medical procedures, including a novel, oral solution
for paediatric sedation now approved in several markets in the
European Union. Primex Pharmaceuticals is headquartered in
Switzerland.

www.primexpharma.com

About POA Pharma:

POA Pharma is a market-oriented Boutique Healthcare Company
present in 9 competence areas with offices in Denmark, Finland,
Norway, Sweden and US. The home Market is the Nordic countries were
POA represents 12 Pharmaceutical producers from 10 countries. POA
Pharma contributes to better healthcare, better health and wellbeing
and a higher quality of life.

www.poapharma.com

ots Originaltext: Primex Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
, please contact:
Primex Pharmaceuticals AG
Alan Knox, CEO
Zug, Switzerland
Tel. +41 (0)79 1762420
alan.knox@primexintl.com
POA Pharma Scandinavia AB
Tina Madsen Sandstr?m
Gothenburg, Sweden
Tel. +46 (0) 31 788 05 99
tina.madsen@poaab.com
© Primex Pharmaceuticals AG, Zug, Switzerland. All rights reserved
Logo: https://mma.prnewswire.com/media/824543/PrimexPharma_Logo.jpg

Original-Content von: Primex Pharmaceuticals, übermittelt durch news aktuell